SCINAI IMMUNOTHERAPEUTICS LTD. Financials Scinai Immunotherapeutics Ltd.
Equities
BVXV
US09073Q3039
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.6 USD | +60.46% |
|
+95.54% | -5.95% |
| 06-17 | Top Premarket Gainers | MT |
| 05-15 | Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 31.17 | 93.45 | 32.39 | 43.42 | 10.32 | 2.591 |
| Enterprise Value (EV) 2 | 49.65 | 152.3 | 90.13 | 59.12 | 17.78 | 18.28 |
| P/E ratio | -0.36 x | -0.69 x | -6.99 x | -0.83 x | -0.74 x | -0.36 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -0.65 x | -1.96 x | 10.2 x | -1.77 x | -1.69 x | -1.99 x |
| EV / FCF | -0.84 x | -2.4 x | -14.9 x | -4.18 x | -2.07 x | -3.1 x |
| FCF Yield | -119% | -41.7% | -6.7% | -23.9% | -48.2% | -32.3% |
| Price to Book | -1 x | -1.44 x | -2.22 x | 1.9 x | -5.52 x | -0.61 x |
| Nbr of stocks (in thousands) | 65.4 | 101 | 115 | 185 | 349 | 435 |
| Reference price 3 | 477.0 | 929.0 | 281.0 | 235.0 | 29.60 | 5.954 |
| Announcement Date | 30/04/19 | 12/06/20 | 13/05/21 | 28/03/22 | 17/04/23 | 15/05/24 |
1USD in Million2ILS in Million3USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -76.81 | -77.65 | 8.84 | -33.31 | -10.5 | -9.192 |
| EBIT 1 | -77.07 | -78.35 | 7.334 | -34.83 | -11.06 | -9.706 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -87.73 | -109.2 | -4.455 | -39.98 | -5.796 | -6.5 |
| Net income 1 | -87.73 | -109.2 | -4.455 | -39.98 | -5.796 | -6.5 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -1,342 | -1,337 | -40.20 | -283.2 | -40.00 | -16.64 |
| Free Cash Flow 1 | -59.26 | -63.51 | -6.04 | -14.14 | -8.578 | -5.904 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 30/04/19 | 12/06/20 | 13/05/21 | 28/03/22 | 17/04/23 | 15/05/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -3.402 | -2.492 | -3.301 | 1.123 | -6.77 | -3.186 | -2.595 | -2.102 | -1.823 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -3.343 | -2.831 | -3.935 | 1.089 | -0.568 | - | -3.762 | 3.107 | - |
| Net income 1 | -2.86 | -3.343 | -2.831 | -3.935 | 1.089 | -0.568 | -3.515 | -3.762 | 3.107 | -10.67 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -25.30 | -24.80 | -23.93 | -0.6120 | 0.2900 | - | -12.00 | -12.00 | 8.000 | -24.00 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 30/11/21 | 28/03/22 | 01/06/22 | 25/08/22 | 30/11/22 | 17/04/23 | 15/05/23 | 11/08/23 | 31/10/23 | 15/05/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 18.5 | 58.8 | 57.7 | 15.7 | 7.47 | 15.7 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.2406 x | -0.7574 x | 6.532 x | -0.4713 x | -0.7112 x | -1.707 x |
| Free Cash Flow 1 | -59.3 | -63.5 | -6.04 | -14.1 | -8.58 | -5.9 |
| ROE (net income / shareholders' equity) | -701% | 227% | 11.2% | -915% | 1,490% | 205% |
| ROA (Net income/ Total Assets) | -51.4% | -44.2% | 5.31% | -27.8% | -23.4% | -27.2% |
| Assets 1 | 170.8 | 247.1 | -83.91 | 143.7 | 24.78 | 23.86 |
| Book Value Per Share 2 | -478.0 | -647.0 | -127.0 | 124.0 | -5.360 | -9.840 |
| Cash Flow per Share 2 | 1,161 | 720.0 | 81.70 | 287.0 | 42.90 | 10.50 |
| Capex 1 | 23.7 | 7.43 | 6.13 | 0.43 | 0.84 | 0.64 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 30/04/19 | 12/06/20 | 13/05/21 | 28/03/22 | 17/04/23 | 15/05/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -5.95% | 2.6M | |
| +38.66% | 52.85B | |
| +35.65% | 38.24B | |
| -7.81% | 38.87B | |
| -10.77% | 26.79B | |
| +11.77% | 26.16B | |
| -17.82% | 19.9B | |
| +35.09% | 13.18B | |
| +29.17% | 12.24B | |
| -3.05% | 11.79B |
- Stock Market
- Equities
- BVXV Stock
- Financials Scinai Immunotherapeutics Ltd.